Cita APA (7a ed.)
Moon, H., Ike, C., Morris, V. A., Wangia Dixon, R., Tonnu-Mihara, I., Crowe, C. L., . . . Barron, J. (2024 Supplement 10). Real-world (rw) treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic tx and avelumab 1L maintenance (1LM): Results from the IMPACT UC-III study. Journal of Clinical Oncology, 42, 390-403.
Cita Chicago Style (17a ed.)
Moon, Helen, Chiemeka Ike, Valerie A. Morris, Ruth Wangia Dixon, Ivy Tonnu-Mihara, Christopher L. Crowe, Malvika Venkataraman, Mairead Kearney, y John Barron. "Real-world (rw) Treatment (tx) Patterns and Clinical Outcomes Among Patients (pts) with Metastatic Urothelial Carcinoma (mUC) Receiving First-line (1L) Systemic Tx and Avelumab 1L Maintenance (1LM): Results from the IMPACT UC-III Study." Journal of Clinical Oncology 42 (2024 Supplement 10): 390-403.
Cita MLA (9a ed.)
Moon, Helen, et al. "Real-world (rw) Treatment (tx) Patterns and Clinical Outcomes Among Patients (pts) with Metastatic Urothelial Carcinoma (mUC) Receiving First-line (1L) Systemic Tx and Avelumab 1L Maintenance (1LM): Results from the IMPACT UC-III Study." Journal of Clinical Oncology, vol. 42, 2024 Supplement 10, pp. 390-403.
Precaución: Estas citas no son 100% exactas.